Overview

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Fluorouracil
Gemcitabine
Paclitaxel